Nami received SBIR Phase II support from NCI

Nami Therapeutics Corp. received a $2M SBIR Phase II grant from National Institute of Health National Cancer Institute (NCI) to translate their nanoparticle-based radiopharmaceutical product to the clinic for treating metastatic ovarian cancer. The Nami team is fully committed to using novel nanotechnologies to improve cancer treatment and provide patients another chance of a cancer free life.

Share this post